Table 1.
Baseline characteristics for the study population (primary analysis)
| Variable | All Subjects (n=158) |
|---|---|
| Age, yr | 70±12.8 |
| Women | 81 (51.3) |
| White race | 106 (67.1) |
| Comorbidities | |
| Coronary artery disease | 20 (12.7) |
| Congestive heart failure | 33 (20.9) |
| Diabetes mellitusa | 43 (27.2) |
| Hypertensive renal disease | 62 (52.9) |
| Glomerulonephropathy | 33 (20.9) |
| Vascular access: catheter | 93 (61.6) |
| Body mass index (kg/m2) | 26.9±7.2 |
| Systolic BP (mmHg) | 144.9±24.2 |
| Diastolic BP (mmHg) | 72.3±12.7 |
| Urea reduction ratio | 70.2±7.8 |
| Laboratory data | |
| BUN (mg/dl) | 46 (38–57) |
| Hemoglobin (g/dl) | 10.5 (9.6–11.3) |
| Albumin (g/dl) | 3.5 (3.2–3.8) |
| Ferritin (ng/ml) | 183 (85–355) |
| Transferrin saturation (%) | 19 (14–25) |
| Phosphorus (mg/dl) | 4.4 (3.7–5.5) |
| Parathyroid hormone (pg/ml) | 225 (117–351) |
| IL-6 (pg/ml) | 16.7 (7.3–39.2) |
| Myeloperoxidase (ng/ml) | 37.5 (20.0–69.3) |
| Weekly EPO dose (units) | 15,228 (7642–27,533) |
| Weekly EPO dose (units)/EDW | 187 (98–385) |
Categorical data are n (%). Continuous measures are mean ± SD. Laboratory values and erythropoietin (EPO) dose are median (quartile 1 to quartile 3). EDW, estimated dry weight of the patient in kilograms.
a
Diabetes mellitus includes all subjects with diabetic kidney disease as cause of ESRD.